Aralez Pharmaceuticals’ (NASDAQ:ARLZ) share price fell 60% today, leaving the Street at odds over when it will hit a bottom. The reason?
Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced new data for YOSPRALA™, a recently FDA-approved prescription fixed-dose combination of aspirin, an anti-platelet agent, and omeprazole, a …